靶向GCK通路:针对RAS突变多发性骨髓瘤的新型选择性治疗策略
多发性骨髓瘤中NRAS、KRAS或BRAF突变见于高达50%的新诊断患者。研究鉴定生发中心激酶(GCK)为RAS突变MM的新型治疗靶点。GCK敲低在体外和体内抑制MM细胞生长,伴随MKK4/7-JNK磷酸化阻断及IKZF1/3、BCL-6、c-MYC降解受损。GCK抑制剂TL4-12剂量依赖性下调IKZF1和BCL-6,抑制增殖并诱导凋亡。
要点
- GCK是RAS突变MM细胞的新型治疗靶点
- GCK激酶活性对MM细胞增殖和存活至关重要
- GCK抑制剂TL4-12可抑制MM细胞增殖并诱导凋亡
核心结论
- GCK是RAS突变MM细胞的新型靶点,为治疗RAS突变MM提供依据。
- GCK抑制剂可能作为克服免疫调节药物耐药的替代疗法。
研究设计与样本
- 研究采用MM细胞系进行体外和体内实验,包括GCK敲低和过表达挽救实验。
- 使用GCK抑制剂TL4-12处理MM细胞评估其效应。
主要发现
- GCK敲低在体外和体内诱导MM细胞生长抑制,伴随MKK4/7-JNK磷酸化阻断及IKZF1/3、BCL-6、c-MYC降解受损。
- 过表达shRNA抗性GCK可挽救GCK敲低效应,排除脱靶效应。
- 过表达激酶失活突变体K45A抑制MM细胞增殖,且不能挽救GCK敲低对MM生长的抑制。
- RASMut细胞对GCK敲低更敏感。
- GCK抑制剂TL4-12剂量依赖性下调IKZF1和BCL-6,抑制MM细胞增殖并诱导凋亡。
临床怎么用
- 对于携带RAS突变的MM患者,靶向GCK可能增加治疗效率并克服耐药。
- GCK抑制剂可能作为免疫调节药物耐药MM患者的替代治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In multiple myeloma (MM), frequent mutations of NRAS, KRAS, or BRAF are found in up to 50% of newly diagnosed patients. The majority of the NRAS, KRAS, and BRAF mutations occur in hotspots causing constitutive activation of the corresponding proteins. Thus, targeting RAS mutation in MM will increase therapeutic efficiency and potentially overcome drug resistance. We identified germinal center kinase (GCK) as a novel therapeutic target in MM with RAS mutation. GCK knockdown (KD) in MM cells demonstrated in vitro and in vivo that silencing of GCK induces MM cell growth inhibition, associated with blocked MKK4/7-JNK phosphorylation and impaired degradation of IKZF1/3, BCL-6, and c-MYC. These effects were rescued by overexpression of a short hairpin RNA (shRNA)-resistant GCK, thereby excluding the potential off-target effects of GCK KD. In contrast, overexpression of shRNA-resistant GCK kinase-dead mutant (K45A) inhibited MM cell proliferation and failed to rescue the effects of GCK KD on MM growth inhibition, indicating that GCK kinase activity is critical for regulating MM cell proliferation and survival. Importantly, the higher sensitivity to GCK KD in RASMut cells suggests that targeting GCK is effective in MM, which harbors RAS mutations. In accordance with the effects of GCK KD, the GCK inhibitor TL4-12 dose-dependently downregulated IKZF1 and BCL-6 and led to MM cell proliferation inhibition accompanied by induction of apoptosis. Here, our data identify GCK as a novel target in RASMut MM cells, providing a rationale to treat RAS mutations in MM. Furthermore, GCK inhibitors might represent an alternative therapy to overcome immunomodulatory drug resistance in MM.
引用
- Li S, Fu J, Yang J, et al. Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma. Blood. 2021. PMID: 33036022. doi:10.1182/blood.2020006334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。